News Releases

Year

Nov 17, 2020

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

65% Complete Response Rate at Three Months Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method ; Median Duration of Response was Not Reached Treatment with UGN-102 was Generally Well Tolerated, with Mostly Mild to Moderate Adverse

Nov 11, 2020

Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021

PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 11, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has

Nov 10, 2020

UroGen Pharma Announces November 2020 Conference Schedule

PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 10, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in

Nov 09, 2020

UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto ® Net Product Revenue of $3.5 Million in First Full Quarter of Commercialization Management Team Expanded to Drive Platform Expansion and Growth

Nov 02, 2020

UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020

Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 2, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Oct 05, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)--Oct. 5, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that, on October 1, 2020 , the Compensation

Sep 10, 2020

UroGen Pharma Announces September 2020 Conference Schedule

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following

Sep 09, 2020

UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth

Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly Henderson Named Chief Financial Officer Jason Smith Named General Counsel and Chief Compliance Officer Polly A.

Sep 04, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)--Sep. 4, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units

Aug 27, 2020

UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence

Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue to Explore Use of the RTGel Hydrogel Formulation with AbbVie’s

Current page 1
Page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on